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The tumor suppressor protein p53 is known to be
transported to the nucleus along microtubular tracks by
cytoplasmic dynein. However, the connection between
p53 and the dynein motor protein complex has not been
established. Here, we show that hsp90binding immu-
nophilins link p53hsp90 complexes to dynein and that
prevention of that linkage in vivo inhibits the nuclear
movement of p53. First, we show that p53hsp90 hetero-
complexes from DLD-1 human colon cancer cells contain
an immunophilin (FKBP52, CyP-40, or PP5) as well as
dynein. p53hsp90immunophilindynein complexes can
be formed by incubating immunopurified p53 with rab-
bit reticulocyte lysate, and we show by peptide compe-
tition that the immunophilins link via their tetratri-
copeptide repeat domains to p53-bound hsp90 and by
means of their PPIase domains to the dynein complex.
The linkage of immunophilins to the dynein motor is
indirect by means of the dynamitin component of the
dynein-associated dynactin complex, and we show that
purified FKBP52 binds directly by means of its PPIase
domain to purified dynamitin. By using a temperature-
sensitive mutant of p53 where cytoplasmic-nuclear
movement occurs by shift to permissive temperature,
we show that p53 movement is impeded when p53 bind-
ing to hsp90 is inhibited by the hsp90 inhibitor radicicol.
Also, nuclear movement of p53 is inhibited when immu-
nophilin binding to dynein is competed for by expres-
sion of a PPIase domain fragment in the same manner as
when dynein linkage to cargo is dissociated by expres-
sion of dynamitin. This is the first demonstration of the
linkage between an hsp90-chaperoned transcription
factor and the system for its retrograde movement to the
nucleus both in vitro and in vivo.
The tumor suppressor protein p53 is a transcription factor
that can induce cell growth arrest, apoptosis, cell differentia-
tion, and DNA repair in response to DNA strand breakage and
other types of cell stress (1–3). p53 mutations occur in more
than half of all human tumors (4), and inactivation of p53 is the
most common alteration found in human cancer (5, 6). Al-
though most p53 mutations in human tumors are located in the
DNA-binding domain and inactivate its transcriptional activity
(4), p53 inactivation may occur in other ways (2).
As has been shown for steroid receptors and some other
transcription factors, p53 shuttles between the cytoplasm and
nucleus (7, 8), and one mechanism of inactivation is exclusion
of p53 from the nucleus (9, 10). The cytoplasmic localization of
mutant p53 may have multiple mechanisms, such as increased
nuclear export (11) and attachment to cytoplasmic anchor pro-
teins (12). Like unliganded steroid receptors (13), some cyto-
plasmic p53 mutants retained in the cytoplasm were found to
be in heterocomplex with the abundant and ubiquitous protein
chaperone hsp90 (14, 15). These p53hsp90 heterocomplexes
are formed by the same hsp90/hsp70-based chaperone machin-
ery (16) that assembles steroid receptor heterocomplexes (13).
One effect of heterocomplex assembly between hsp90 and its
“client” proteins is to stabilize the client protein to degradation
by the ubiquitin-proteasome pathway of proteolysis (17); this
has been shown for p53 (18, 19), where its binding to hsp90
inhibits MDM2-dependent ubiquitination (20). The dynamic
formation of heterocomplexes with hsp90 and its associated
immunophilins is also required for rapid ligand-induced move-
ment of aryl hydrocarbon and glucocorticoid receptors (GR)1 to
the nucleus (21, 22). Partial but complementary sets of obser-
vations regarding the mechanisms of GRhsp90 and p53hsp90
movement have been made that will be connected in this work
to form a more complete model of the retrograde movement of
p53.
GRhsp90 heterocomplexes immunoadsorbed from cell ly-
sates contain cytoplasmic dynein (23, 24), a molecular motor
that processes along microtubular tracks toward the nucleus
(25). These heterocomplexes also contain one of several immu-
nophilins with tetratricopeptide repeat (TPR) domains that
interact with a TPR acceptor site on hsp90 (13). The immu-
nophilins are widely expressed proteins with peptidylprolyl
isomerase (PPIase) domains that bind immunosuppressant
drugs of the FK506 and cyclosporine A class. GRhsp90 hetero-
complexes contain one of four TPR domain immunophilins:
FKBP52, FKBP51, CyP-40, or PP5, the latter being a protein
phosphatase that also contains TPR and PPIase homology do-
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mains (13, 26). In these complexes, the PPIase domain func-
tions as a protein-protein binding domain to link the GRhsp90
unit to cytoplasmic dynein (27–29).
Although the linkage to the dynein motor has been in large
part worked out for the GR, it has not been demonstrated that
receptor movement is dynein-dependent. In contrast, p53
movement to the nucleus has been shown to be dynein-depend-
ent, and it is immunoadsorbed in complexes that contain tubu-
lin and cytoplasmic dynein (30); however, the linkage of p53 to
dynein has not been defined. Here, we demonstrate that
p53hsp90 and GRhsp90 heterocomplexes from DLD-1 human
colon cancer cells exist in identical heterocomplexes containing
cytoplasmic dynein and one of three immunophilins, FKBP52,
CyP-40, or PP5. Competition with peptides in vitro shows that
the PPIase domain of the immunophilin is required for dynein
presence in the p53hsp90 heterocomplexes. The immunophilin
linkage to dynein is indirect by means of the dynamitin com-
ponent of the dynein-associated dynactin complex, and we
show that purified FKBP52 binds directly via its PPIase do-
main to immunopurified dynamitin. Expression of the immu-
nophilin PPIase domain fragment in HT29-tsp53 cells inhibits
nuclear translocation of p53 when cells are shifted to permis-
sive temperature in the same manner as expression of myc-
dynamitin. Our observations demonstrate that the hsp90-bind-
ing immunophilins are required both for p53 linkage to dynein
in vitro and for dynein-dependent transport of p53 to the nu-
cleus in vivo.
EXPERIMENTAL PROCEDURES
Materials—DLD-1 human colorectal adenocarcinoma cells were pur-
chased from the American Type Culture Collection (Manassas, VA).
HT29-tsp53 (formerly referred to as ts29-G cells) human colorectal
cancer cell line overexpressing a mouse p53 temperature-sensitive mu-
tant was described in previous works (31, 32). The Ab421 pan-specific
mouse monoclonal antibody against p53 was kindly provided by Dr.
Michael F. Clarke (University of Michigan Medical School). The Ab-4
mouse monoclonal IgG against mouse p53 and Ab-7 sheep antiserum
against p53 were purchased from Calbiochem (La Jolla, CA). The A-14
rabbit polyclonal IgG and the 9E10 mouse monoclonal IgG against
c-myc oligopeptide were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). The MAB1618 mouse monoclonal IgG against the
74-kDa intermediate chain subunit of cytoplasmic dynein was pur-
chased from Chemicon International (Temecula, CA). The JJ3 mono-
clonal IgG against p23 was provided by Dr. David Toft (The Mayo
Clinic, Rochester, MN). The UPJ56 rabbit antiserum against FKBP52
was a kind gift from Dr. Karen Leach (Amersham Biosciences). The
FiGR mouse monoclonal IgG used to immunoadsorb the GR was kindly
provided by Dr. Jack Bodwell (Dartmouth Medical School, Lebanon,
NH). The BuGR2 mouse monoclonal IgG used to immunoblot the GR
and the rabbit polyclonal antibody against CyP-40 were from Affinity
BioReagents (Golden, CO). The AC88 mouse monoclonal IgG against
hsp90 and the N27F3–4 mouse monoclonal IgG against hsp70/hsc70
were from StressGen BioReagents (Victoria, BC, Canada). 125I-Conju-
gated goat anti-mouse and anti-rabbit IgGs were from PerkinElmer
Life Sciences. Horseradish peroxidase-conjugated goat anti-rabbit IgG
was from Pierce. Horseradish peroxidase-conjugated goat anti-mouse,
donkey anti-sheep antibodies, radicicol, and geldanamycin were ob-
tained from Sigma. Rhodamine-conjugated goat anti-mouse IgG and
FITC-conjugated donkey anti-rabbit IgG were obtained from Jackson
ImmunoResearch (West Grove, PA). The baculovirus for the FLAG-
tagged TPR domain of rat PP5 (33) and the rabbit antiserum against
PP5 were kindly provided by Dr. Michael Chinkers (University of South
Alabama, Mobile, AL). The pGEX1T plasmid encoding the GST-rabbit
FKBP52 Gly32-Lys138 expression vector that comprises the PPIase core
domain I (provided by Drs. Michel Renoir and Christine Radanyi,
UMR8612 CNRS, Paris, France) and the purification of the PPIase core
domain I protein were described previously (23, 34). The mammalian
expression plasmid pSG5PL-PPIase core domain I was described in a
previous work (23). The pEGFP-C3 plasmid encoding for Aequorea
victoria green fluorescent protein was from Clontech (Palo Alto, CA).
The myc-tagged pCMVH50m construct encoding for p50/dynamitin (35)
was a kind gift from Dr. Richard B. Vallee (University of Massachusetts
Medical School, Worcester, MA); Opti-MEM-I transfection medium was
from Invitrogen; Trans-Fast transfection reagent was from Promega
(Madison, WI); rabbit reticulocyte lysate was from Green Hectares
(Oregon, WI); and Complete-Mini protease inhibitor mixture tablets
were purchased from Roche Diagnostics (Mannheim, Germany).
Cell Culture—DLD-1 cells were grown at 37 °C in T-162 culture
flasks containing 30 ml of Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum, 2 mM L-glutamine, 1.5 g/liter
NaHCO3, 4.5 g/liter glucose, and 1 mM pyruvate. HT29-tsp53 were
grown at 39 °C (non-permissive temperature) on 22 22 mm coverslips
placed on 35-mm plates in 2 ml of Dulbecco’s modified Eagle’s medium
containing 10% bovine calf serum and 2 mM L-glutamine. 293-T Human
fibroblasts were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 10% bovine calf serum and antibiotics. All cultures were
maintained under a 5% CO2 atmosphere.
Immunoadsorptions—Confluent DLD-1 cells were harvested by
scraping into ice-cold Earle’s balanced saline, washed twice, and rup-
tured by Dounce homogenization in one volume of HE buffer (10 mM
Hepes, 1 mM EDTA, pH 7.4) supplemented with 20 mM Na2MoO4 and
one tablet of protease inhibitor mix per 3 ml of buffer. Homogenates
were centrifuged at 3 °C for 30 min at 100,000  g, the resultant
supernatant being referred to as cytosol. For immunoadsorption of p53
or the GR, 250 l of DLD-1 cytosol was incubated for 3 h at 4 °C with
either 10 l of Ab421 antibody or 7 l of FiGR antibody and 16 l of
protein-A Sepharose. The pellets were washed four times with 1 ml of
TEG buffer (10 mM TES, pH 7.6, 50 mM NaCl, 4 mM EDTA, 10% (v/v)
glycerol, and protease inhibitors) containing 20 mM Na2MoO4. Immune
pellets were resolved on SDS-12% polyacrylamide gels and transferred
to Immobilon-P membranes. The membranes were probed with 0.1%
Ab421 for p53, 0.25 g/ml BuGR2 for GR, 1 g/ml AC88 for hsp90, 1
g/ml N27F3–4 for hsp70, 0.1% MAB1618 for dynein, 0.1% UPJ56 for
FKBP52, 0.1% anti-CyP-40, 0.1% anti-PP5, 0.1% JJ3 mouse ascites for
p23, or 0.1% A-14 for myc-dynamitin. The immunoblots were then
incubated a second time with the appropriate 125I-conjugated or horse-
radish peroxidase-conjugated counter-antibody to visualize immunore-
active bands. p53 was revealed by enhanced chemiluminescence. Be-
cause PP5, FKBP52, p53, and dynamitin migrate in the same region on
gel electrophoresis, as do hsp70 and the dynein intermediate chain, we
electrophoresed replicate samples of both non-immune and immune
pellets and probed replicate immunoblots with antibody specific for
each protein. Thus, the Western blots of Figs. 1, 2, and 6 are necessarily
composites prepared from two or more replicate immunoblots.
Heterocomplex Reconstitution—DLD-1 cytosol was prepared in HE
buffer without molybdate. After immunoadsorbing p53, coadsorbed pro-
teins were dissociated from the immune pellet by incubating for 2 h
with TEG buffer supplemented with 500 mM NaCl. The pellet was
washed twice with TEG buffer and twice with 10 mM Hepes buffer at pH
7.4. p53hsp90 heterocomplexes were then assembled by incubating the
stripped immune pellets with 50 l of rabbit reticulocyte lysate and 5 l
of an ATP-regenerating system (50 mM ATP, 250 mM creatine phos-
phate, 20 mM magnesium acetate, and 100 units/ml of creatine phos-
phokinase). The assembly mixtures were incubated for 30 min at 30 °C,
with suspension of the pellets by shaking the tubes every 2–3 min.
Pellets were then washed four times with 1 ml of ice-cold TEG buffer
supplemented with 20 mM Na2MoO4 and boiled in SDS-sample buffer.
In peptide competition experiments, the reticulocyte lysate was prein-
cubated for 30 min at 30 °C with either 10 l of lysate (8 mg of
protein/ml) of Sf9 cells expressing the TPR domain fragment of rat PP5
or with 30 g of purified PPIase domain fragment of rabbit FKBP52
(29).
Cell Transfection—When HT29-tsp53 cells were50% confluent, the
culture medium was replaced by Opti-MEM transfection medium con-
taining 5% bovine calf serum, and the incubation continued for 1 h as
described above. The medium was aspirated and replaced by a trans-
fection mixture (at a 3 l liposome/1 g of DNA ratio) preincubated for
15 min at room temperature in Opti-MEM, which contained either 0.4
g of pCMVH50m or 1.0 g pEGFP-C3 and 4.0 g of pSG5PL-PPIase
core domain I. Controls were transfected with pCMV or pEGFP-C3 and
pSG5PL. After 1.5 h of transfection, the mixture was replaced by
regular medium and the cells were incubated for an additional 24 h at
the non-permissive temperature of 39 °C. The expression of dynamitin
was evidenced by indirect immunofluorescence with an anti-myc anti-
body, and the co-transfection of EGFP and the PPIase domain I due to
the green fluorescence exhibited by transfected cells. When myc-dyna-
mitin was overexpressed in 293-T human fibroblasts, 6 g of
pCMVH50m plasmid was used. After 48 h, the cells were ruptured by
Dounce homogenization in one volume of HE buffer supplemented with
20 mM Na2MoO4.
Indirect Immunofluorescence—Nuclear translocation of p53 was trig-
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gered by incubating HT29-tsp53 cells at 32 °C. Cells were fixed and
permeabilized by immersion in cold (20 °C) methanol at the indicated
times, and immunostained by inverting the coverslip on 50 l of solu-
tion of phosphate-buffered saline with 1% bovine serum albumin con-
taining 1 l of mouse monoclonal IgG against mouse p53 or 0.5 l of
rabbit polyclonal IgG against the c-myc tag of dynamitin. The coverslips
were washed and reincubated with 1/100 dilution of the corresponding
counter-antibody (rhodamine-conjugate goat anti-mouse IgG and fluo-
rescein isothiocyanate-conjugate donkey anti-rabbit IgG). Cells were
observed with a Leitz Aristoplan epi-illumination microscope and
scored for p53 nuclear translocation as described before for the GR (21):
a score of 4 was used for nuclear fluorescence much greater than
cytoplasmic fluorescence, 3 for nuclear fluorescence greater than cyto-
plasmic fluorescence, 2 for nuclear fluorescence equal to cytoplasmic
fluorescence, 1 for nuclear fluorescence less than cytoplasmic fluores-
cence, and 0 for nuclear fluorescence much less than cytoplasmic fluo-
rescence. The translocation scores represent the mean  S.E. from
three experiments, in which 100 cells/condition/experiment were
counted. Significance was analyzed by one-way analysis of variance
followed by the Bonferroni t test.
Formation of DynamitinImmunophilin Complexes—Cytosol (200 l)
from 293-T cells transfected with myc-dynamitin was incubated with 10
l of 9E10 mouse monoclonal IgG against myc and 16 l of protein-A
Sepharose. After 2 h, 0.5 M NaCl and 0.05% Nonidet P-40 were added
and the incubation was continued for two more hours to strip dynamitin
of associated proteins. After the pellets were washed twice with 1 ml of
TEG buffer and twice with HKD buffer (10 mM Hepes, pH 7.4, 100 mM
KCl, and 2 mM dithiothreitol), they were incubated for 20 min at 30 °C
with 50 l of rabbit reticulocyte lysate and 5 l of the ATP-regenerating
system. The samples were washed 4 with TEG buffer with 20 mM
Na2MoO4 before gel electrophoresis and immunoblotting with rabbit
polyclonal antibody against c-myc oligopeptide and specific rabbit anti-
bodies against immunophilins. Prior to the reconstitution assay, the
lysates were preincubated for 30 min at 30 °C with HKD buffer plus or
minus purified PPIase core domain I of FKBP52. For direct binding of
purified dynamitin to purified FKBP52, myc-dynamitin was immuno-
adsorbed from 293-T cell cytosol and stripped of associated proteins, as
described above. After washing, the immunopellets were incubated for
30 min on ice with FKBP52, purified as described previously (27), in the
presence or absence of purified PPIase domain I of FKBP52. The final
volume was adjusted to 50 l with HKD buffer. Pellets were washed 4
times with TEG buffer with 20 mM Na2MoO4, and proteins were re-
vealed by immunoblotting with rabbit anti-myc antibody and the
UPJ56 anti-FKBP52 antibody.
RESULTS
Composition of p53hsp90 Heterocomplexes in DLD-1
Cells—To examine the composition of native p53hsp90 hetero-
complexes, we selected the DLD-1 human colorectal cancer cell
line, which possesses a point mutation that converts Ser-241 of
p53 to Phe (36). This mutant p53 is localized in the cytoplasm
and exists in cytosolic heterocomplexes with hsp90 (20). In Fig.
1, mutant p53 and the GR were immunoadsorbed from DLD-1
cytosol, and proteins in the washed immunopellets were iden-
tified by immunoblotting. Hsp90 was coadsorbed with both
proteins, as was some hsp70, which is an essential component
of the multiprotein chaperone machinery that forms “client
protein” heterocomplexes with hsp90 (13). Also present in both
heterocomplexes was p23, a ubiquitous 23-kDa acidic protein
that binds to the ATP-dependent conformation of hsp90 when
the client proteinhsp90 complex has been assembled (13). It
has been shown that p23 binds dynamically and stabilizes the
GRhsp90 heterocomplex (37).
The TPR domain immunophilins FKBP52 and CyP-40 are
coimmunoadsorbed with both p53 and the GR, as is PP5 (Fig.
1). Both of these immunophilins and the immunophilin homo-
log PP5 have been shown to exist in cytosols in complexes that
contain cytoplasmic dynein (29). Here, we use an antibody
against the dynein intermediate chain (DIC) to show that dy-
nein is coimmunoadsorbed with both the GR and p53, as pre-
viously reported (23, 24, 30). FKBP51 is another immunophilin
that has been found in steroid receptorhsp90 heterocomplexes,
where it seems to counter the increase in steroid-binding affin-
ity of the hsp90-bound GR caused by FKBP52 (38). Because we
do not have an antibody to determine whether FKBP51 is in
complexes that contain dynein, we have not assayed it here.
Nevertheless, it seems clear from Fig. 1 that the same complex
of proteins is coimmunoadsorbed with p53 as with the GR. The
bands in Fig. 1 are clearly specific for the GR and p53, with
non-immune pellets prepared from the same cytosol showing
the background. However, the GR and p53 heterocomplexes
may not be identical in that they may differ somewhat in the
relative amounts of the immunophilins that are present. The
specificity of the procedure is underlined by two considerations:
the GR is not present in p53 immune pellets, and p53 is not
present in GR immune pellets prepared from the same sample
of cytosol.
Immunophilins Link the p53hsp90 Complex to Dynein—Re-
ticulocyte lysate contains the multiprotein hsp90/hsp70-based
chaperone machinery that assembles client proteinhsp90 het-
erocomplexes (13), and GRhsp90 heterocomplexes assembled
in reticulocyte lysate contain both immunophilins and cyto-
plasmic dynein (23). Fig. 2 shows the reconstitution of
p53hsp90immunophilindynein complexes by rabbit reticulo-
cyte lysate. The native heterocomplex of mutant p53 with hu-
man chaperones and dynein is shown in lane 2. The immuno-
adsorbed p53 was then stripped of its associated proteins (lane
4) and incubated with reticulocyte lysate to reconstitute the
heterocomplex with rabbit proteins (lane 5). In lane 6, p53 was
FIG. 1. Immunoadsorption of p53 and GR heterocomplexes.
DLD-1 cell cytosol was incubated with non-immune mouse IgG (NI) or
with antibody (I) against p53 or the GR. The immunopellets were
washed, and proteins were resolved by SDS-polyacrylamide gel electro-
phoresis and immunoblotting for the indicated proteins.
FIG. 2. Effects of geldanamycin and competition with TPR and
PPIase domain peptides on p53 heterocomplexes assembled by
reticulocyte lysate. p53 was immunoadsorbed from DLD-1 cytosol
with the Ab421 antibody, and the p53-associated proteins were stripped
from the immunopellet with NaCl (conditions 3-8). The stripped p53
immunopellets were incubated with reticulocyte lysate, washed, and
proteins were resolved by electrophoresis and immunoblotting. Lane 1,
cytosol immunoadsorbed with non-immune IgG; lane 2, cytosol immu-
noadsorbed with Ab421 antibody; lane 3, stripped non-immune pellet
incubated with reticulocyte lysate; lane 4, stripped immune pellet in-
cubated with buffer; lane 5, stripped immune pellet incubated with
reticulocyte lysate; lane 6, stripped immune pellet incubated with re-
ticulocyte lysate containing 10 M geldanamycin; lane 7, stripped im-
mune pellet incubated with reticulocyte lysate preincubated with the
TPR domain fragment of rat PP5; lane 8, stripped immune pellet
incubated with reticulocyte lysate preincubated with the PPIase do-
main fragment of FKBP52.
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incubated with reticulocyte lysate that was treated with
geldanamycin, an ansamycin antibiotic that binds to the
unique N-terminal ATP site of hsp90 and inhibits its function
(39). When hsp90 binding is blocked, there are no immunophi-
lins or dynein associated with p53. Also, when the TPR do-
main fragment of PP5 is present to compete for immunophilin
binding to p53-bound hsp90, p53hsp90 complexes are formed that
lack immunophilins and dynein (lane 7). When the PPIase domain
fragment of FKBP52 is present (lane 8), p53hsp90immunophilin
complexes are formed that lack dynein. Thus, in vitro, the immu-
nophilins link the p53hsp90 complex to dynein.
Radicicol Inhibits p53 Transport to the Nucleus—To examine
the movement of p53 from the cytoplasm to the nucleus, we
chose HT29-tsp53 cells, a stable human colon carcinoma cell
line expressing a temperature-sensitive allele of murine p53
(31). This temperature-sensitive mutant of p53 is fully active
and nuclear at the permissive temperature of 32 °C, but it is
inactive and located in the cytoplasm at the non-permissive
temperature of 39 °C (40–42). To inhibit hsp90 function, we
used radicicol rather than geldanamycin. Geldanamycin has a
quinone moiety that redox cycles in vivo to produce hydrogen
peroxide (43), which induces nuclear translocation of p53 (44).
Radicicol inhibits hsp90 in the same manner as geldanamycin
(45), but it does not possess a quinone moiety and does not
cause oxidant production (43).
Inhibition of the cytoplasmic-nuclear transport of p53 by 5
M radicicol is shown in Fig. 3. By 60 min after the cells are
switched from 39 to 32 °C, all of the p53 has progressed from
the cytoplasm to the nucleus in vehicle-treated cells, whereas
only partial movement has occurred in the presence of radicicol
(Fig. 3A). From the time course of the radicicol effect shown in
Fig. 3B, it is clear that movement is inhibited. However, the
movement is not blocked, and by 90 min, most of the p53 has
translocated to the nucleus in cells treated with 5 M radicicol.
In some other intact cell systems, 20 M radicicol has been
required for substantial inhibition of hsp90 (43). Unfortu-
nately, at concentrations of 10 M radicicol and above, the
HT29-tsp53 cells detach from the plastic, and we have not been
able to determine whether higher concentrations of drug pro-
duce a greater inhibition of nuclear transport.
Inhibition of p53 Transport by Expression of a PPIase Do-
main Fragment—To show that the overexpressed, tempera-
ture-sensitive, mutant mouse p53 in HT29-tsp53 cells under-
goes dynein-dependent movement to the nucleus as reported
for wild-type human p53 (30), p53 movement was examined in
HT29-tsp53 cells expressing myc-dynamitin. Dynamitin is a
50-kDa subunit of the dynein-associated dynactin complex, and
its overexpression blocks dynein function by dissociating the
motor from its cargoes (35, 46). In HT29-tsp53 cells overex-
pressing dynamitin (Fig. 4A, green), there was very little move-
ment of p53 (Fig. 4A, red) compared with surrounding non-
transfected cells where p53 accumulated in the nucleus after
the switch to permissive temperature. Overexpression of the
PPIase domain fragment of FKBP52 also inhibited p53 move-
ment (Fig. 5A). The extent of inhibition of p53 movement by the
PPIase domain fragment (Fig. 5B) was similar to the inhibition
produced by overexpression of dynamitin (Fig. 4B).
Immunophilin Interaction with Dynamitin—The observa-
tions that the PPIase domain fragment competed for the bind-
ing of p53hsp90immunophilin complexes to dynein (Fig. 2)
and that overexpression of the PPIase domain fragment inhib-
ited p53 translocation to the nucleus (Fig. 5) are consistent
with a model in which the immunophilin PPIase domain links
the p53hsp90immunophilin complex to the protein motor for
retrograde movement. However, it is not yet clear what part of
the dynein/dynactin complex interacts directly with the PPIase
domain. We have demonstrated previously a very weak inter-
action between the PPIase domain fragment of FKBP52 and
the purified expressed intermediate chain of mouse cytoplas-
mic dynein (29). However, PPIase domains engage in weak
interactions with peptidyl prolines (47), and this binding could
be nonspecific in this way. Cytoplasmic dynein is thought to
link vesicles and organelles indirectly through dynactin (46),
and it is possible that overexpression of dynamitin inhibits p53
nuclear translocation (Fig. 4), because it is dynamitin itself
that is the component of the dynactin complex that interacts
directly with the immunophilin PPIase domain.
If dynamitin binds directly to the immunophilin PPIase do-
main, then it should be present in immunoadsorbed p53 het-
erocomplexes. Because we do not have an antibody directed
against dynamitin, we transfected DLD-1 cells with myc-dyna-
mitin, immunoadsorbed p53 complexes, and probed Western
blots of the immunoadsorbate with anti-myc antibody to detect
the presence of dynamitin. As shown in Fig. 6A, dynamitin
coimmunoadsorbed with p53 (lane 2), and its presence was
eliminated by competition with the PPIase domain fragment of
FKBP52 (lanes 3 and 4). To determine whether dynamitin
binds TPR domain immunophilins, myc-dynamitin was immu-
noadsorbed to protein-A Sepharose, stripped of associated pro-
teins by incubation with salt, and the immunopellet was incu-
bated with reticulocyte lysate in the presence or absence of the
PPIase domain fragment. It can be seen in Fig. 6B that the
FIG. 3. p53 translocation to the nucleus is impeded by radici-
col. A, HT29-tsp53 colon cancer cells were preincubated for 15 min in
the presence of 5 M radicicol (RAD) or 0.1% vehicle (DMSO), and p53
translocation to the nucleus was triggered by shifting the temperature
from 39 to 32 °C. At the indicated times, the cells were fixed and
permeabilized in cold methanol and then immunostained by incubating
with the Ab-4 monoclonal IgG against mouse p53, followed by incubat-
ing with rhodamine-conjugated goat anti-mouse IgG. Bar, 10 m. B,
p53 nuclear translocation in cells treated with either vehicle (E) or
radicicol () was scored as described under “Experimental Procedures”
and plotted against the incubation time at the permissive temperature.
Results are the mean  S.E. of three independent experiments. *, p 
0.03, significant difference.
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stripped dynamitin (lane 1) bound to the three hsp90-binding
immunophilins, PP5, FKBP52 and CyP-40 (lane 2), and the
immunophilins were not bound if the PPIase domain fragment
was present to compete for their binding (lane 3). To determine
whether the immunophilin is directly interacting with dyna-
mitin, we incubated immunoadsorbed, stripped myc-dynamitin
with purified FKBP52. As shown in Fig. 6C, stripped dyna-
mitin (lane 3) bindsFKBP52 (lane 4). This binding is competed
by the purified FKBP52 PPIase domain fragment (lanes 5 and
6), suggesting a direct interaction between the PPIase domain
of the immunophilin and the dynamitin component of the dy-
nactin complex.
DISCUSSION
We show here that the immunophilins link the p53hsp90
complex to cytoplasmic dynein in vitro (Fig. 2) and that pre-
venting that interaction by overexpression of the PPIase do-
main fragment inhibits p53 movement to the nucleus in vivo
(Fig. 5). As illustrated in the cartoon in Fig. 7, the key linkages
involve immunophilin binding to hsp90 by means of the TPR
domain and binding to the dynamitin component of the dynein-
associated dynactin complex by means of the PPIase domain
(Fig. 6). Neither binding of the immunophilins to dynein (26)
nor the rate of transport of the GR (23) or p53 (data not shown)
to the nucleus is affected by FK506. Thus, although the PPIase
domain interacts with the dynein/dynactin complex, PPIase
activity is not required for the interaction.
TPR domain immunophilins are distributed widely among
animal and plant cells, and both the TPR domain binding to
hsp90 and PPIase domain linkage to the dynein motor complex
are conserved interactions (28, 48). This suggests that the TPR
domain immunophilins perform a rather fundamental function
or functions, and that there may be considerable redundancy in
their action. The hsp90 binding TPR domain immunophilins
were discovered as components of the steroid receptorhsp90
heterocomplexes (13), and their functions have not been
broadly studied for other transcription factors. Their presence
as components that link p53 to the motor protein responsible
for its retrograde movement is consistent with a broad role for
these immunophilins in protein trafficking to the nucleus. The
only other clear demonstration of a TPR domain immunophilin
effect is that the binding of FKBP52 to the GRhsp90 hetero-
complex increases the affinity of steroid binding in a manner
that requires the immunophilin PPIase activity (38). However,
this effect seems to be specific to FKBP52, and it is clearly
limited to the GR as opposed to other steroid receptors.
The immunophilins bind after the client proteinhsp90 het-
erocomplex has been assembled, and by cross-linking steroid
receptor complexes, Gehring and his colleagues determined a
heterotetrameric structure of 1 receptor:2 hsp90:1 immunophi-
lin (reviewed in Ref. 49). This is the stoichiometry we suggest
for the p53hsp90immunophilin complex in Fig. 7. The differ-
FIG. 4. Overexpression of dynamitin inhibits p53 movement to
the nucleus. A, HT29-tsp53 cells were transfected with pCMVH50m
plasmid encoding for myc-tagged dynamitin (Dyt). p53 nuclear translo-
cation was triggered by shifting the temperature from 39 to 32 °C. The
cells were double-stained for p53 (red) and dynamitin (green). Arrows,
transfected cells. Bar, 10 m. B, rate of nuclear translocation of p53
(mean  S.E., n  3) in cells transfected with empty vector (E) or with
dynamitin (). *, p  0.005, significant difference.
FIG. 5. Overexpression of the PPIase domain I fragment of
FKBP52 inhibits p53 movement to the nucleus. A, HT29-tsp53
cells were co-transfected with pSG5PL-PPIase core domain I and
pEGFP-C3 plasmids encoding for the PPIase domain of rabbit FKBP52
(Gly32-Lys138) and green fluorescent protein. p53 nuclear translocation
was triggered by shifting the temperature from 39 to 32 °C, and cells
were immunostained for p53 (red). Arrows, transfected cells. Bar, 10
m. B, rate of nuclear translocation of p53 (mean  S.E., n  3) in cells
transfected with empty vector (E) or with the PPIase domain (). *, p
0.005, significant difference.
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ent immunophilins compete with each other for binding to
hsp90, and they exist in separate GRhsp90 heterocomplexes
(49). Nevertheless, the number of TPR acceptor sites per hsp90
dimer is somewhat controversial. Saturation binding (50) and
cross-linking (27) studies are consistent with one TPR binding
site per hsp90 dimer, whereas isothermal titration calorimetry
studies are consistent with the binding of two molecules of TPR
protein per hsp90 dimer (51, 52).
As p53 acts by regulating transcription, its translocation
from the cytoplasm into the nucleus is required for the biolog-
ical response. The demonstration by Giannakakou et al. (30)
that p53 is transported to the nucleus by dynein provided an
important advance in understanding the mechanism of nuclear
translocation. Here, we have used p53 mutants that localize to
the cytoplasm to show the similarity between p53 heterocom-
plexes and those of the glucocorticoid receptor, another hsp90-
regulated transcription factor. This has allowed us to identify
the hsp90-binding immunophilins as the linkers between
p53hsp90 and the dynein motor complex. The observations of
Fig. 6 suggest that the hsp90-binding immunophilins link di-
rectly via their PPIase domains to dynamitin, which in turn
connects the complex to the dynein motor. This movement
model should provide an important advance in understanding
how a variety of proteins that act in the nucleus are trans-
ported to that organelle.
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